Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
The lancet. Gastroenterology & hepatology（2023）
摘要
Janssen Research and Development.
更多查看译文
关键词
ulcerative colitis,golimumab monotherapy,golimumab combination therapy,double-blind,proof-of-concept
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要